Our previous studies demonstrated promising outcomes after haploidentical donor transplant combined with unrelated umbilical cord blood (haplo-cord- hematopoietic stem cell transplantation [HSCT]) for hematological disorders. However, clinical profiling regarding chronic graft-versus-host disease (cGVHD) has not yet been fully described under this protocol. This study analyzed the clinical characteristics of cGVHD among 300 patients with hematological malignancies who received haplo-cord-HSCT between January 2012 and July 2016 at our center. During the follow-up, the 5-year cumulative incidence of cGVHD based on the National Institutes of Health (NIH) consensus criteria was 32.2% (95% confidence interval [CI], 28.7–35.7); the 5-year cumulative incidence of moderate to severe cGVHD was 11.4% (95% CI, 9.4–13.4). After the multivariate analysis, the GVHD overall survival (GOS) was associated with relapse, thrombocytopenia, bronchiolitis obliterans syndrome, and steroid-refractory cGVHD. The infused CD34+ cells (≥3.46 × 106/kg) from haploidentical grafts were a protective factor affecting GOS. This study proposed a nomogram for predicting GOS using the aforementioned five variables. The concordance index was 0.877 (95% CI, 0.859–0.895) for the accuracy evaluation of the nomogram. Our results suggested that the 5-year cumulative incidence of NIH-defined cGVHD after haplo-cord-HSCT was 32.2%, and this nomogram may help clinicians select reasonable treatment strategies.
Get full access to this article
View all access options for this article.
References
1.
WingardJR, NS MajhailR B, razauskasZ W, angKA, SobocinskiD J, acobsohnML, SorrorMM, HorowitzB Bolwell, et al. (2012). Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol, 29:2230–2239.
2.
AroraM, CS CutlerMH, JagasiaJ P, idalaX C, haiPJ, MartinME, FlowersY I, namotoGLChen, et al. (2016). Late acute and chronic graft-versus-host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant, 22:449–455.
3.
AraiS, M AroraT W, angSR, SpellmanW He, DR CourielA U, rbano-IspizuaCS, CutlerAABacigalupo, et al. (2015). Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant, 21:266–274.
4.
MitchellSA, NK LeidyKH, MooneyWN, DudleySL, BeckPC, LaStayoEW, CowenP P, alitLEComis, et al. (2010). Determinants of functional performance in long-term survivors of allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). Bone Marrow Transplant, 45:762–769.
5.
PasswegJR, H BaldomeroP B, aderC B, oniniS C, esaroP D, regerRF, DuarteC D, ufourJHFalkenburg, et al. (2015). Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants. Bone Marrow Transplant, 50:476–482.
6.
WangY, QF LiuLP, XuKY, LiuXH, ZhangX Ma, ZPFan, WuDP and XJHuang. (2015). Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood, 125: 3956–3962.
7.
AnasettiC, D AmosPG, BeattyFR, AppelbaumW B, ensingerCD, BucknerR C, liftK D, oneyPJMartin, et al. (1989). Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med, 320:197–204.
8.
AnasettiC, PG BeattyR S, torbPJ, MartinM M, oriJESanders, ThomasED and JAHansen. (1990). Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol, 29:79–91.
9.
AversaF, A TabilioA T, erenziA V, elardiF F, alzettiC G, iannoniR I, acucciT Z, eiMPMartelli, et al. (1994). Successful engraftment of T-cell depleted haploidentical three loci incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony stimulating factor mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood, 84:3948–3955.
10.
AversaF, A TerenziA T, abilioF F, alzettiA C, arottiS B, allantiR F, eliciniF F, alcinelliA Velardi, et al. (2005). Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol, 23:3447–3454.
11.
CiureaSO, MJ ZhangAA, BacigalupoA B, asheyFR, AppelbaumOS, AljitawiP A, rmandJH, AntinJ Chen, et al. (2015). Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood, 126:1033–1040.
12.
GaoL, Y ZhangB Hu, J LiuP K, ongS L, ouY Su, T YangH Li, et al. (2016). Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation. J Clin Oncol, 34:2843–2850.
13.
TakahashiS, J OoiA T, omonariT K, onumaN T, sukadaM O, iwa-MonnaK F, ukunoM U, chiyamaK Takasugi, et al. (2007). Comparative single-institute analysis of cord blood transplantation from unrelated donors with bone marrow or peripheral blood stem-cell transplants from related donors in adult patients with hematologic malignancies after myeloablative conditioning regimen. Blood, 109:1322–1330.
14.
GutmanJA, K RossC S, mithH M, yintCK, LeeR S, alitF M, ilanoC D, elaneyD Gao, et al. (2016). Chronic graft versus host disease burden and late transplant complications are lower following adult double cord blood versus matched unrelated donor peripheral blood transplantation. Bone Marrow Transplant, 51:1588–1593.
ChenJ, RX WangF C, henAN, SunHY, QiuZM, JinXW, TangY H, anZZFu, et al. (2014). Combination of a haploidentical SCT with an unrelated cord blood unit: a single-arm prospective study. Bone Marrow Transplant, 49:206–211.
17.
KeP, XB BaoXH, HuJ Z, huangXJ, WuYJ, LiuXF, HeDP, WuSLXue, et al. (2018). Myeloablative conditioning regimens with combined of haploidentical and cord blood transplantation for myelodysplastic syndrome patients. Bone Marrow Transplant, 53:162–168.
18.
WagnerJE, JN BarkerTE, DeForKS, BakerBR, BlazarC E, ideA G, oldmanJ K, erseyW Krivit, et al. (2002). Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival. Blood, 100:1611–1618.
19.
FilipovichAH, D WeisdorfS P, avleticG S, ocieJR, WingardSJ, LeeP M, artinJ C, hienD Przepiorka, et al. (2005). National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant, 11:945–956.
20.
JagasiaMH, HT GreinixM A, roraKM, WilliamsD W, olffEW, CowenJ P, almerD W, eisdorfNSTreister, et al. (2015). National Institutes of Health Consensus Development Project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group Report. Biol Blood Marrow Transplant, 21:389–401.
21.
LeeSJ, Vogelsang G and ME Flowers. (2003). Chronic graft versus host disease. Biol Blood Marrow Transplant, 9:215–233.
22.
WolffD, M Schleuning, S von HarsdorfU B, acherA G, erbitzM S, tadlerF A, yukA K, ianiR Schwerdtfeger, et al. (2011). Consensus Conference on Clinical Practice in chronic GVHD: second-line treatment of chronic graft-versus-host disease. Biol Blood Marrow Transplant, 17:1–17.
23.
WangY, YJ ChangLP, XuKY, LiuDH, LiuXH, ZhangH C, henW H, anYHChen, et al. (2014). Who is the best donor for a related HLA haplotype-mismatched transplant?. Blood, 124:843–850.
24.
HoltanSG, TE DeForA L, azaryanN B, ejanyanM A, roraCG, BrunsteinBR, BlazarML, MacMillan and DJ Weisdorf. (2015). Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation. Blood, 125:1333–1338.
25.
ChoBS, CK MinKS, EomYJ, KimHJ, KimS L, eeSG, ChoDW, KimJW Lee, et al. (2009). Feasibility of NIH consensus criteria for chronic graft-versus-host disease. Leukemia, 23:78–84.
26.
MoonJH, SK SohnA L, ambieL E, llisN H, amadJ U, hmV G, uptaJH, LiptonHAMessner, et al. (2014). Validation of National Institutes of Health global scoring system for chronic graft-versus-host disease (GVHD) according to overall and GVHD-specific survival. Biol Blood Marrow Transplant, 20:556–563.
27.
GooleyTA, W Leisenring, Crowley J and BE Storer. (1999). Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med, 18:695–706.
28.
HarrellFE Jr, LeeKL and DBMark. (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med, 15:361–387.
29.
HosmerDW, T Hosmer, Le Cessie S and S Lemeshow. (1997). A comparison of goodness-of-fit tests for the logistic regression model. Stat Med, 16:965–980.
30.
SociéG and JRitz. (2014). Current issues in chronic graft-versus-host disease. Blood, 124:374–384.
31.
MacDonaldKP, HillGR and BRBlazar. (2017). Chronic graft-versus-host disease: biological insights from preclinical and clinical studies. Blood, 129:13–21.
32.
WangY, F ChenY H, anZZ, FuXW, TangM M, iaoHY, QiuZM, JinANSun, et al. (2009). Partially matched related hematopoietic stem cell transplantation without ex vivo T cell depletion compared with matched unrelated transplantation in adult patients with hematologic malignancies. Biol Blood Marrow Transplant, 15:1258–1264.
33.
WangY, DH LiuKY, LiuLP, XuXH, ZhangW H, anH C, henYH, ChenFRWang, et al. (2013). Long-Term Follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. Cancer, 119:978–985.
34.
LeeKH, JH LeeJH, LeeDY, KimM S, eolYS, LeeYA, KangM J, eonHJHwang, et al. (2011). Reduced-intensity conditioning therapy with busulfan, fludarabine, and antithymocyte globulin for HLA-haploidentical hematopoietic cell transplantation in acute leukemia and myelodysplastic syndrome. Blood, 118:2609–2617.
35.
RaiolaAM, A Dominietto, C di GraziaT L, amparelliF G, ualandiA I, baticiS B, reganteMT, Van LintR Varaldo, et al. (2014). Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant, 20:1573–1579.
36.
BasheyA, X ZhangK J, acksonS B, rownM R, idgewayM S, olhLEMorris, HollandHK and SRSolomon. (2016). Comparison of outcomes of hematopoietic cell transplants from T-replete haploidentical donors using post-transplantation cyclophosphamide with 10 of 10 HLA-A, -B, -C, -DRB1, and -DQB1 allele-matched unrelated donors and HLA-identical sibling donors: a multivariable analysis including disease risk index. Biol Blood Marrow Transplant, 22:125–133.
37.
Van Besien KH L, iuN Jain, Stock W and A Artz. (2013). Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications. Biol Blood Marrow Transplant, 19:682–691.
38.
CutlerAJ, V Limbani, Girdlestone J and CV Navarrete. (2010). Umbilical cord-derived mesenchymal stromal cells modulate monocyte function to suppress T cell proliferation. J Immunol, 185:6617–6623.
39.
AroraM, JP KleinDJ, WeisdorfA Hassebroek, FlowersME and CSCutler. (2011). Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. Blood, 117:6714–6720.
40.
BalachandranVP, M Gonen, SmithJJ and RPDeMatteo. (2015). Nomograms in oncology: more than meets the eye. Lancet Oncol, 16:e173–e180.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
